FOx Biosystems
0653.744.366 · rovalta.com · 22/09/2026
OPENING OF BANKRUPTCY
FOx Biosystems
Financial year 2023 · closed on 31/12/2023
Net result
-2,8 M €
+16.4% YoY
Gross margin
-763,9 k €
+47.7% YoY
Equity
1,3 M €
-47.9% YoY
Workforce
13,8 ETP
+14.0% YoY
Company — Opening of bankruptcy.
Overview
What does FOx Biosystems do?
FOx Biosystems is a Public limited company incorporated in 2016. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Diepenbeek. It employs on average 13,8 ETP workers (FTE).
Legal situation
● Opening of bankruptcy
BCE/KBO no. / VAT
BE 0653.744.366
Incorporation
03/05/2016
Legal form
Public limited company
Registered office
Agoralaan Abis
3590 Diepenbeek · FlandreSee on map
3590 Diepenbeek · FlandreSee on map
Contributed capital
4 530 207,96 €
Latest accounts
31/12/2023
Average workforce
13,8 ETP
Activities (NACE)
72101Research and experimental development on natural sciences and engineering· main72110Research and experimental development on biotechnology70210Public relations and communication activities73300Advertising and market research74909Other professional, scientific and technical activities n.e.c.74999Other professional, scientific and technical activities n.e.c.
Joint committees (2)
- 200
- 2000
Contacts
4 public details availableLog in to view
Signals
Solid equityGood liquidityHealthy social debts
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 8 financial years
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||||
| Gross margin | -763,9 k € | +47.7% | -1,5 M € | -39.7% | -1 M € | -250% | -298,9 k € | +1.5% | -303,4 k € | -270% | -82 k € | +11.2% | -92,4 k € | -8227% | -1,1 k € |
| EBITDA | -2,3 M € | +12.0% | -2,6 M € | -45.7% | -1,8 M € | -118% | -821,2 k € | -94.3% | -422,7 k € | -412% | -82,6 k € | +11.3% | -93,1 k € | -6291% | -1,5 k € |
| Operating result | -2,9 M € | +11.1% | -3,3 M € | -36.3% | -2,4 M € | -97.8% | -1,2 M € | -107% | -585,3 k € | -491% | -99 k € | -4.9% | -94,4 k € | -6380% | -1,5 k € |
| Net result | -2,8 M € | +16.4% | -3,3 M € | -46.1% | -2,3 M € | -100% | -1,1 M € | -152% | -452,8 k € | -357% | -99,2 k € | -5.0% | -94,4 k € | -6382% | -1,5 k € |
| Balance sheet | |||||||||||||||
| Equity | 1,3 M € | -47.9% | 2,5 M € | +87.2% | 1,3 M € | -63.9% | 3,7 M € | +22.3% | 3 M € | +208010% | -1,4 k € | -101% | 97,7 k € | +470% | 17,1 k € |
| Total assets | 2,7 M € | -9.5% | 3 M € | -32.4% | 4,4 M € | +13.8% | 3,9 M € | +23.7% | 3,2 M € | +2025% | 148,7 k € | +25.5% | 118,5 k € | +591% | 17,1 k € |
| Cash | 620,9 k € | -54.6% | 1,4 M € | -43.2% | 2,4 M € | +36.7% | 1,8 M € | +46.2% | 1,2 M € | +2318% | 49,8 k € | -16.9% | 59,9 k € | +252% | 17 k € |
| Debts | 639,1 k € | +64.6% | 388,3 k € | -86.8% | 3 M € | +1116% | 242,7 k € | +44.9% | 167,5 k € | +11.6% | 150,1 k € | +623% | 20,8 k € | – | |
| Other | |||||||||||||||
| Workforce | 13,8 ETP | +14.0% | 12,1 ETP | +34.4% | 9,0 ETP | – | – | – | – | – | |||||
Governance
Board of directors
Seen on filing of 31/12/2023 · 8 active · 21 ended
Active mandates
Jerry Williamson
ActiveMark Truesdale
ActiveActive
Active
Bart Geers
ActiveFilip Delport
ActiveJeroen Lammertyn
ActiveEnded mandates
At this address
Other companies at this address
| Company | CBE no. |
|---|---|
Bedal International● Active | 0841.685.826 |
BIOCLUE● Active | 0719.914.105 |
BIOKEY● Active | 0719.913.808 |
BIOSTRAND● Active | 0719.913.907 |
Clinitude● Active | 0478.640.857 |
C-Path● Active | 0762.683.482 |
Highstar Engineering● Active | 0685.983.703 |
IDEA FAMILY● Active | 0719.674.177 |
NanoBiotech● Active | 1023.651.490 |
Presscuff● Active | 0800.361.153 |
Reprosci Biosciences● Active | 1008.398.241 |
Sealantium Medical Belgium● Active | 1012.599.727 |
SIMABS● Active | 0732.709.096 |
| 1011.224.604 | |
StingOrg● Active | 0804.587.383 |
Financials
Annual accounts
Full financial information
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 | 01/01/2019 | 01/01/2018 |
| Closing of the financial year | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 | 31/12/2019 | 31/12/2018 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 09/07/2024 | 04/07/2023 | 08/07/2022 | 08/07/2021 | 16/03/2021 | 10/07/2019 |
| General meeting | 28/06/2024 | 29/06/2023 | 30/06/2022 | 10/06/2021 | 10/07/2020 | 13/06/2019 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
9 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2023 | 28/06/2024 | 09/07/2024 | Dutch | |
| Abridged model | 31/12/2022 | 29/06/2023 | 04/07/2023 | Dutch | |
| Abridged model | 31/12/2021 | 30/06/2022 | 08/07/2022 | Dutch | |
| Micro model | 31/12/2020 | 10/06/2021 | 08/07/2021 | Dutch | |
| Micro modelCorrection | 31/12/2019 | 10/07/2020 | 16/03/2021 | Dutch | |
| Micro model | 31/12/2019 | 10/07/2020 | 15/07/2020 | Dutch | |
| Micro model | 31/12/2018 | 13/06/2019 | 10/07/2019 | Dutch | |
| Micro model | 31/12/2017 | 28/06/2018 | 16/07/2018 | Dutch | |
| Micro model | 31/12/2016 | 02/06/2017 | 12/06/2017 | Dutch |
Valuation
Estimate
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Governance
Board of directors
Seen on filing of 31/12/2023 · 8 active · 21 ended
Active mandates
Jerry Williamson
ActiveMark Truesdale
ActiveActive
Active
Bart Geers
ActiveFilip Delport
ActiveJeroen Lammertyn
ActiveEnded mandates
Shareholders
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette
Belgian Official Gazette publications
- Capital / shares09/08/2024STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN
- Mandates30/07/2024ONTSLAGEN - BENOEMINGEN
- Mandates13/05/2024STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
- Mandates07/12/2023ONTSLAGEN - BENOEMINGEN
- Mandates10/03/2023ONTSLAGEN - BENOEMINGEN
- Capital / shares13/12/2022KAPITAAL - AANDELEN
- Mandates05/10/2022ONTSLAGEN - BENOEMINGEN
- Capital / shares07/01/2021KAPITAAL - AANDELEN
Source: Belgian Official Gazette
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2023Annual accounts 2023-2,8 M €↑
- 2022Annual accounts 2022-3,3 M €↓
- 2021Annual accounts 2021-2,3 M €↓
- 2020Annual accounts 2020-1,1 M €↓
- 2019Annual accounts 2019-452,8 k €↓
- 2018Annual accounts 2018-99,2 k €↓
- 2018Name changeFox Biosystems
- 2017Annual accounts 2017-94,4 k €↓
- 2016Annual accounts 2016-1,5 k €
- 03/05/2016IncorporationPublic limited company
- 2016Name changeFOx Diagnostics